Drug Discovery World
MAY 6, 2024
During the period 2016-2021, the Brazilian, Chinese and Indian markets grew by 11.7%, 6.7% respectively compared to an average market growth of 5.8% for the top five European Union markets and 5.6% for the US market 2. However, Europe is facing increasing competition from emerging economies.
Pharma Marketing Network
DECEMBER 21, 2020
those that modify the expression of an individual’s genes or repair abnormal genes) has entered clinical practice, including 11 RNA therapeutics, 2 in vivo gene therapies, and 2 gene-modified cell therapies. Almost two decades after the human genome was sequenced, a trickle of new genetic medicines (i.e., Am J Bioeth.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cloudbyz
MARCH 6, 2024
For example, monoclonal antibodies, a type of biologic, can selectively bind to specific targets such as proteins or cells involved in disease processes, thereby modulating immune responses or inhibiting disease progression.
pharmaphorum
NOVEMBER 2, 2021
Dr Laura Moriarty, senior marketing manager at Bio-Rad, looks at the impressive immuno-therapeutic potential of bispecific antibodies (bsAbs). The BiTE platform is an innovative technology designed to engage the immune system against numerous stages and types of cancers. Dr Laura Moriarty is senior marketing manager at Bio-Rad.
Drug Discovery World
MAY 30, 2023
Erin Goodhue, Director of Clinical Research and Development, and Dawn Faller, Senior Manager, Global Clinical Marketing, Therapeutic Systems, Terumo Blood and Cell Technologies: “When thinking about cancer, breast cancer has surpassed lung cancer as the most diagnosed cancer worldwide with one in eight women diagnosed in their lifetime.
Pharma Marketing Network
JANUARY 20, 2021
It’s widely acknowledged that optimal vaccine immunity results from engaging both humoral and cellular responses, but less attention has been given to the role of mucosal immunity in protecting against COVID-19, which is surprising considering SARS-CoV-2 enters the human body primarily through the mucosal surfaces of the upper respiratory tract.
The Pharma Data
DECEMBER 27, 2020
Notably, we never modify the DNA of these cells, which avoids some of the safety concerns that have been reported with certain gene-editing technologies. Finally, we seek to generate compelling clinical data to support moving into late-stage clinical trials and eventual marketing authorizations.
Expert insights. Personalized for you.
59 
Let's personalize your content